Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Recruiting Phase 4 Interventional

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

NCT07569926
View directory record Official record
Conditions
Prostate Cancer
Interventions
fluciclovine (18F)
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

NCT00638378
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Highland, California • Montebello, California • Mountain View, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 31, 2026, 10:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

NCT03436485
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ODM-208, Midazolam
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Minneapolis, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Results available

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

NCT00424385
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gleevec + Sorafenib
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Niles, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

NCT04616547
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Questionnaire Administration, Tin Sn 117m Pentetate
Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

NCT01095848
View directory record Official record
Conditions
Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Biological
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

NCT01799278
View directory record Official record
Conditions
Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer, Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
Interventions
MLN8237
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Chicago, Illinois • Detroit, Michigan • New Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Not applicable Interventional Results available

Prostate Resection After Microwave Ablation (PRAMA)

NCT06128525
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Microwave Ablation, Multiparametric Magnetic Resonance Imaging, Questionnaire Administration, Radical Prostatectomy
Procedure · Device · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

NCT01790126
View directory record Official record
Conditions
Prostate Cancer
Interventions
ARN-509, LHRH Agonist
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 31, 2026, 10:50 AM EDT
Recruiting Not applicable Interventional

Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

NCT05519878
View directory record Official record
Conditions
Bladder Carcinoma, Genitourinary System Neoplasm, Kidney Carcinoma, Prostate Carcinoma
Interventions
Best Practice, Bright White Light Therapy, Occupational Therapy, Questionnaire Administration
Other · Device · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

NCT01059643
View directory record Official record
Conditions
Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck
Interventions
LY2523355, pegfilgrastim
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jonesboro, Arkansas • Jacksonville, Florida • Macon, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 31, 2026, 10:50 AM EDT
Not yet recruiting Not applicable Interventional

Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL)

NCT07836933
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms, Patient Education as Topic
Interventions
AI-guided COUNSEL Intervention, Questionnaires
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Not applicable Interventional

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

NCT04604158
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Glioblastoma, Prostate Cancer, Gynecologic Cancer, Colorectal Cancer, Sarcoma, Kidney Cancer, Bladder Cancer, Lymphoma, Leukemia, Head and Neck Cancer, Pancreas Cancer, Multiple Myeloma, Anxiety, Social Isolation, Stress, Loneliness, Melanoma, Uterine Cancer
Interventions
Elly Mobile Phone Application
Behavioral
Lead sponsor
Gillian Gresham
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

NCT02740985
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions
AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors

NCT00350233
View directory record Official record
Conditions
Bone Metastases
Interventions
ExAblate 2000
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 31, 2026, 10:50 AM EDT
Not listed Phase 2 Interventional

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

NCT01296243
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tesetaxel
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • New Brunswick, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 31, 2026, 10:50 AM EDT
Active, not recruiting Not applicable Interventional

The Genomic Medicine at VA Study

NCT04331535
View directory record Official record
Conditions
Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions
Polygenic risk score (PRS)
Diagnostic Test
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
50 Years to 70 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Recruiting Not applicable Interventional

Multilevel Intervention for Precision Oncology

NCT06825715
View directory record Official record
Conditions
Advanced Cancers of the Prostate, Cancers of the Lung
Interventions
Multilevel intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
2,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

NCT04264208
View directory record Official record
Conditions
Prostate Cancer
Interventions
68-Ga RM2., 68-Ga PSMA11, PET/MRI
Drug · Device
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 31, 2026, 10:50 AM EDT
Completed No phase listed Observational

Prostate Cancer Patients With Biochemical Recurrence

NCT03527199
View directory record Official record
Conditions
Patients With Prostate Cancer
Interventions
Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)
Diagnostic Test
Lead sponsor
Medhat Osman
Federal
Eligibility
18 Years to 89 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 31, 2026, 10:50 AM EDT
Terminated No phase listed Observational

Prostatectomy Prospective Database

NCT00447616
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 31, 2026, 10:50 AM EDT
Completed Not applicable Interventional

Effects of GCP on Prostate Cancer.

NCT00269555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genistein Combined Polysaccharide (GCP)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 31, 2026, 10:50 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Plant-based Diets and Risk of Cancer in the Adventist Health Study-2

NCT03615599
View directory record Official record
Conditions
Cancer, Breast, Cancer, Colorectal, Cancer, Prostate
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
30 Years and older
Enrollment
96,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2028
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 31, 2026, 10:50 AM EDT
Completed No phase listed Observational

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

NCT03662204
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Bladder Cancer, Uterine Cancer, Kidney Cancer, Renal Pelvis Cancer, Pancreatic Cancer, Liver Cancer, Stomach Cancer, Ovarian Cancer, Esophageal Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
5,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
119
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 31, 2026, 10:50 AM EDT